Compare COEP & IGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | COEP | IGI |
|---|---|---|
| Founded | 2017 | N/A |
| Country | United States | United States |
| Employees | 6 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 91.2M | 97.0M |
| IPO Year | N/A | 2009 |
| Metric | COEP | IGI |
|---|---|---|
| Price | $16.52 | $16.11 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 47.1K | 12.4K |
| Earning Date | 05-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.80 | $15.78 |
| 52 Week High | $21.41 | $17.09 |
| Indicator | COEP | IGI |
|---|---|---|
| Relative Strength Index (RSI) | 72.18 | 41.17 |
| Support Level | $13.77 | $15.78 |
| Resistance Level | $19.19 | $16.59 |
| Average True Range (ATR) | 1.15 | 0.14 |
| MACD | 0.47 | -0.01 |
| Stochastic Oscillator | 87.62 | 24.61 |
Coeptis Therapeutics Holdings Inc is a biopharmaceutical and technology company. The biopharmaceutical division focuses on developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Coeptis aims to advance treatment paradigms and improve patient outcomes through its research and development efforts. The technology division focuses on enhancing operational capabilities through technologies. This division features AI-powered marketing software and robotic process automation tools designed to optimize business processes and improve overall efficiency. It derives the majority of the revenue from the Technology segment.
Western Asset Invstm Grd Dfnd Opp Tr Inc operates as a non-diversified closed-end management investment company. Its primary investment objective is to provide current income and then liquidate & distribute substantially all of the Fund's net assets to stockholders. As a secondary investment objective, the Fund will seek capital appreciation. The Fund seeks to achieve its investment objectives by investing at least 80% of its net assets in investment-grade corporate fixed-income securities of varying maturities.